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Abstract
Background: Hospitalized COVID-19 patients tend to be older and frequently have hypertension, diabetes, or coronary heart disease, but 
whether these comorbidities are true risk factors (ie, more common than in the general older population) is unclear. We estimated associations 
between preexisting diagnoses and hospitalized COVID-19 alone or with mortality, in a large community cohort.
Methods: UK Biobank (England) participants with baseline assessment 2006–2010, followed in hospital discharge records to 2017 and death 
records to 2020. Demographic and preexisting common diagnoses association tested with hospitalized laboratory-confirmed COVID-19 
(March 16 to April 26, 2020), alone or with mortality, in logistic models.
Results: Of 269 070 participants aged older than 65, 507 (0.2%) became COVID-19 hospital inpatients, of which 141 (27.8%) died. Common 
comorbidities in hospitalized inpatients were hypertension (59.6%), history of fall or fragility fractures (29.4%), coronary heart disease 
(21.5%), type 2 diabetes (type 2, 19. 9%), and asthma (17.6%). However, in models adjusted for comorbidities, age group, sex, ethnicity, 
and education, preexisting diagnoses of dementia, type 2 diabetes, chronic obstructive pulmonary disease, pneumonia, depression, atrial 
fibrillation, and hypertension emerged as independent risk factors for COVID-19 hospitalization, the first 5 remaining statistically significant 
for related mortality. Chronic kidney disease and asthma were risk factors for COVID-19 hospitalization in women but not men.
Conclusions: There are specific high-risk preexisting comorbidities for COVID-19 hospitalization and related deaths in community-based 
older men and women. These results do not support simple age-based targeting of the older population to prevent severe COVID-19 infections.
Keywords:  COVID-19, Epidemiology, Morbidity, Mortality
The 2019 novel coronavirus (SARS-CoV-19) (1) presents with a 
wide spectrum of clinical disease presentations, from asymptomatic 
infection to respiratory failure with high mortality (2). However, 
little is known about what predicts hospitalization or mortality with 
COVID-19 in different individuals.
The majority of patients hospitalized with COVID-19 are older 
and have underlying medical conditions (3,4), with increased age 
being associated with clinical severity (5,6), including case fatality 
(4,7). The most frequent comorbidities reported in Chinese COVID-
19 patient cohorts were hypertension (21.1%, 95% confidence 
interval [CI]: 13.0%–27.2%), diabetes (9.7%, 95% CI: 7.2%–
12.2%), cardiovascular disease (8.4%, 95% CI: 3.8%–13.8%), 
and respiratory system disease (1.5%, 95% CI: 0.9%–2.1%) (8), 
whereas in a large US cohort common comorbidities were hyper-
tension (56.6%), obesity (41.7%), and diabetes (33.8%) (6). Data 
on common comorbidities in hospitalized patients are important 
for understanding the acute treatment challenge, but it is unclear 
whether these conditions are common in COVID-19 hospital in-
patients merely because they are also common in the older popula-
tion. To identify those living in the community who are at most risk 
of hospitalization with COVID-19 (alone or with mortality), data 
are needed on which preexisting conditions are disproportionately 
common in such inpatients compared to the background population.
UK Biobank (UKB) is a community-based cohort of 500 000 
participants currently aged 48–86 (9). Electronic linkage between 
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results in England are available from March 16 to April 26, 2020, 
thus including the peak of daily COVID-19 laboratory-confirmed 
cases in the current outbreak (10). During this period, testing of 
older groups was largely restricted to hospital inpatients with clin-
ical signs of infection (11), so test positivity is considered a good 
marker of severe COVID-19 (12). Given the scarcity of cohort data 
on risk factors for hospitalized COVID-19 in older groups, including 
those who died, we analyzed baseline (2006–2010) demographic 
characteristics and preexisting diagnoses during UKB follow-up. 
Identifying the specific risk factors explaining why some older people 
in the community were hospitalized with COVID-19 (of whom a 
subset died) may give clues to underlying vulnerabilities and are crit-
ical to developing outbreak control policies that focus on individual 
risk and avoid imposing crude age-based public health controls (13).
Method
UKB Cohort
The UKB consists of more than 500 000 community volunteers aged 
40–70 years at baseline (2006–2010), living close to 22 assessment 
centers in England, Scotland, and Wales (9). Baseline assessments in-
cluded demographics, lifestyle, and disease history, with linkages to 
electronic medical records. UK Biobank ethical approval was from 
the North West Multi-centre Research Ethics Committee. The cur-
rent analysis was approved under the UKB application 14631 (PI, 
D.M.).
COVID-19 Test Status and Sample Selection
Data were from UKB participants with linked data on COVID-19 
infection (by polymerase chain reaction) from tests performed be-
tween March 16 and April 26, 2020, in England only (14) and linked 
data on death records to April 26, 2020. We excluded participants 
who tested positive for COVID-19 but were not recorded as being 
hospital inpatients on the test sample submitted to the laboratory. 
We restricted analyses to participants aged 65 years and older when 
tested (or age on April 26, 2020 if not tested), to minimize misclassi-
fication of disease severity from health care workers. We also ex-
cluded UKB participants reported to have died before the pandemic 
(set as February 1, 2020). No COVID-19 test data were available 
for UKB assessment centers in Scotland and Wales, so data from 
these centers were not included. Our outcomes of interest were (a) 
COVID-19 test positive compared to the rest of the sample (ie, test 
negative and untested samples) and (b) COVID-19 test positive and 
died versus the rest of the sample, but with the additional exclusion 
of participants testing positive but who were still alive (see Figure 1 
for details of UKB participants included in the analyses).
Disease Ascertainment
Preexisting diagnoses were available from baseline questionnaires 
(2006–2010) eliciting participant reports of doctor-diagnosed 
disease. New disease diagnoses since baseline were from linked elec-
tronic medical records to hospital inpatient routine data (to March 
2017), coded according to the International Classification of Diseases 
10th revision (ICD-10). Diagnoses included were coronary heart 
disease (CHD), atrial fibrillation, stroke, hypertension, diabetes (type 
2), chronic kidney disease (CKD, stages 3–5), depression, dementia, 
asthma, chronic obstructive pulmonary disease (COPD), osteopor-
osis, and osteoarthritis. We also identified previous diagnoses of de-
lirium, pneumonia, and falls or fragility fractures (see definitions in 
Supplementary Table 1). We combined each diagnosis reported at 
baseline or from linked hospital data to generate preexisting diag-
nosis status for each participant.
Statistical Analysis
We estimated associations of demographic and diagnoses with in-
patient COVID-19 test positivity (alone or with mortality) using 
logistic regression models, with 95% CIs. Logistic models were ad-
justed for age group (in 5-year bands), sex, ethnicity, education, and 
assessment center at baseline (to account for geographic differences 
in the prevalence of COVID-19 infection). We performed subgroup 
analyses stratified by sex and tested for interaction terms by sex. We 
also performed sensitivity analyses, comparing inpatient COVID-19 
test positives with those testing negative. A p value smaller than 5% 
was considered statistically significant. All the statistical analyses 
were performed in Stata version 15.1.
Results
There were 269 070 older adults (aged 65–86  years, mean 
73.1 years) eligible for the analysis, of whom 507 (0.2%) were la-
boratory test-positive COVID-19 hospital inpatients, including 
141 (27.8%) certified to have died. Rates of COVID-19 hospi-
talization varied widely across UKB baseline assessment centers 
(0.34%–0.07%; Supplementary Table 2). The mean age of COVID-
19 test-positive inpatients (Table 1) was 74.3 years (SD 4.5), versus 
73.1  years (SD 4.4) for other study participants. Both inpatients 
and others were predominantly of “white” ethnicity, but people 
self-reporting “black” ethnicity made up 3.6% of inpatients but 
only 1% of participants. The most common preexisting diagnoses 
in inpatients were hypertension (59.6%), a history of falls or fra-
gility fractures (29.4%), CHD (21.5%), diabetes (type 2, 19.9%), 
and asthma (17.6%). Dementia was present in 2.8% of inpatients 
Figure 1. Flowchart of UK Biobank participants selected for analyses.
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(0.3% of other participants). COVID-19 inpatients had a mean of 
2.3 preexisting diagnoses (of a possible 15 examined) compared to 
other participants with mean 1.4 diagnoses.
In logistic modeling of demographic variables (Table  2, 
“Demographics”), rates of COVID-19 hospitalization were higher 
in those aged older than 80 years (odds ratio [OR] = 2.02, 95% CI: 
1.41–2.89, p = 1.40E-04) compared to age group 65–69, with no 
statistically significant risk increase in 70–74  years old and inter-
mediate risks in 75–79  years old. Males were substantially more 
likely to be COVID-19 test-positive patients (OR = 1.91, 95% CI: 
1.59–2.29, p  =  5.10E-12) and people of black ethnicity were at 
higher risk (OR  =  3.17, 95% CI: 1.92–5.25, p  =  7.20E-06) com-
pared to white, with South Asians and other ethnicities having 
intermediate risks. Compared to those with degree-level education, 
having no education qualifications (OR = 2.52, 95% CI: 1.96–3.24, 
p = 5.80E-13) was associated with raised risks of COVID-19.
All studied diagnoses individually (adjusted for demographics only) 
were associated with a COVID-19 positive test, with the exception 
of osteoarthritis (Supplementary Table 3). As different chronic dis-
eases often coexist in older adults, we estimated risks for each diag-
nosis accounting for other diagnoses present. In models adjusted for 
demographics and the other studied preexisting diagnoses (Table  2, 
Full model), dementia was associated with the largest increase in 
risk of COVID-19 hospitalization (OR  =  3.50, 95% CI: 1.93–6.34, 
p = 4.3.60E-05), followed by pneumonia (OR = 1.96, 95% CI: 1.45–
2.64, p  =  1.10E-05), depression (OR  =  1.79, 95% CI: 1.37–2.33, 
p = 1.70E-05), diabetes (OR = 1.73, 95% CI: 1.36–2.22, p = 1.20E-05), 
atrial fibrillation (OR = 1.64, 95% CI: 1.24–2.17, p = 5.00E-04), and 
COPD (OR = 1.58, 95% CI: 1.17–2.15, p = 2.90E-03), with a modest 
risk increase with hypertension (OR  =  1.38, 95% CI: 1.13–1.68, 
p = 1.70E-03). Coronary heart disease prevalence, previously noted as 
common in COVID-19 inpatients, did not differ between inpatients and 
other participants (OR = 0.95, 95% CI: 0.74–1.21, p = 6.60E-01) after 
adjustment for other diagnoses.
In logistic models for the risk of COVID-19 hospitalization 
and death, preexisting dementia was associated with the largest 
Table 1. Descriptive Characteristics of UK Biobank Cohort by Inpatient COVID-19 Test Positivity
Inpatient COVID-19 Positive Test Rest of the Cohort
Men Women Total Men Women Total
Total number 311 196 507 121 096 147 467 268 563
Dead 95 (30.6) 46 (23.5) 141 (27.8) 471 (0.4) 344 (0.2) 815 (0.3)
Age (years), mean (SD) 74.7 (4.4) 73.6 (4.6) 74.3 (4.5) 73.3 (4.4) 73.0 (4.4) 73.1 (4.4) 
 65–69 46 (14.8) 51 (26.0) 97 (19.1) 31 522 (26.0) 41 174 (27.9) 72 696 (27.1)
 70–74 102 (32.8) 64 (32.7) 166 (32.7) 44 117 (36.4) 55 532 (37.7) 99 649 (37.1)
 75–79 132 (42.4) 65 (33.2) 197 (38.9) 37 642 (31.3) 42 138 (28.6) 79 780 (29.7)
 80+ 31 (10.0) 16 (8.2) 47 (9.3) 7815 (6.5) 8623 (5.9) 16 438 (6.1)
Ethnicity       
 White 282 (92.2) 171 (87.7) 453 (90.4) 115 714 (96.2) 141 152 (96.1) 256 866 (96.2)
 Black 10 (3.3) 8 (4.1) 18 (3.6) 1108 (0.9) 1618 (1.1) 2726 (1.0)
 South Asian 6 (2.0) 11 (5.6) 17 (3.4) 2204 (1.8) 1996 (1.4) 4200 (1.6)
 Other (including mixed and Chinese) 8 (2.6) 5 (2.6) 13 (2.6) 1278 (1.1) 2057 (1.4) 3335 (1.3)
Education       
 None 119 (40.2) 75 (39.3) 194 (39.8) 25 008 (21.1) 32 786 (22.7) 57 794 (22.0)
 School/College 71 (24.0) 52 (27.2) 123 (25.3) 37 172 (31.4) 48 430 (33.6) 85 602 (32.6)
 Professional qualification 45 (15.2) 26 (13.6) 71 (14.6) 17 763 (15.0) 24 001 (16.6) 41 764 (15.9)
 Degree 61 (20.6) 38 (19.9) 99 (20.3) 38 514 (32.5) 39 044 (27.1) 77 558 (29.5)
Prevalent disease*       
 CHD 80 (25.7) 29 (14.8) 109 (21.5) 19 986 (16.5) 10 949 (7.4) 30 935 (11.5)
 Atrial fibrillation 53 (17.0) 15 (7.7) 68 (13.4) 9164 (7.6) 5097 (3.5) 14 261 (5.3)
 Stroke 15 (4.8) 8 (4.1) 23 (4.5) 3176 (2.6) 2227 (1.5) 5403 (2.0)
 Hypertension 194 (62.4) 108 (55.1) 302 (59.6) 55 772 (46.1) 53 981 (36.6) 109 753 (40.9)
 Diabetes (type 2) 71 (22.8) 30 (15.3) 101 (19.9) 11 004 (9.1) 7518 (5.1) 18 522 (6.9)
 Chronic kidney disease 10 (3.2) 13 (6.6) 23 (4.5) 1814 (1.5) 2061 (1.4) 3875 (1.4)
 Depression 38 (12.2) 35 (17.9) 73 (14.4) 6724 (5.6) 12 749 (8.7) 19 473 (7.3)
 Dementia 7 (2.3) 7 (3.6) 14 (2.8) 412 (0.3) 462 (0.3) 874 (0.3)
 Asthma 39 (12.5) 51 (26.0) 90 (17.6) 14 100 (11.6) 20 512 (13.9) 34 612 (12.9)
 COPD 36 (11.6) 26 (13.3) 62 (12.2) 5790 (4.8) 5656 (3.8) 11 446 (4.3)
 Osteoporosis 9 (2.9) 15 (7.7) 24 (4.7) 1160 (1.0) 6309 (4.3) 7469 (2.8)
 Osteoarthritis 45 (14.5) 41 (20.9) 86 (17.0) 12 987 (10.7) 23 553 (16.0) 36 540 (13.6)
Previous disease/condition*       
 Delirium 4 (1.3) 1 (0.5) 5 (1.0) 320 (0.3) 284 (0.2) 604 (0.2)
 Pneumonia 40 (12.9) 18 (9.2) 58 (11.4) 5146 (4.3) 5051 (3.4) 10 197 (3.8)
 Falls/Fragility fractures 82 (26.4) 67 (34.2) 149 (29.4) 22 531 (18.6) 44 302 (30.0) 66 833 (24.9)
 Number of above diseases (max 15), mean (SD) 2.3 (1.8) 2.4 (1.8) 2.3 (1.8) 1.4 (1.4) 1.4 (1.3) 1.4 (1.4)
 Number of hospital admissions, mean (SD) 5.9 (10.4) 5.1 (7.2) 5.6 (9.3) 3.0 (9.3) 2.7 (5.8) 2.8 (7.6)
Notes: CHD = coronary heart disease; COPD = chronic obstructive pulmonary disease. The numbers presented are n (%) unless otherwise specified. The rest of 
the cohort includes test negative and untested UK Biobank participants.
*Diagnoses from baseline self-report and hospital inpatient admissions.
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risk increase (OR = 7.30, 95% CI 3.28–16.21, p = 1.10E-06), fol-
lowed by diabetes (OR = 3.11, 95% CI: 2.06–4.71, p = 7.60E-08), 
COPD (OR = 1.91, 95% CI: 1.10–3.32, p = 2.20E-02), pneumonia 
(OR  =  1.88, 95% CI: 1.07–3.30, p  =  2.80E-02), and depression 
(OR = 1.78, 95% CI: 1.07–2.96, p = 2.70E-02). Although preva-
lent atrial fibrillation and hypertension were significantly associ-
ated with COVID-19 hospitalization, these diagnoses did not reach 
a significance for being a COVID-19 inpatient and dying (p > .05; 
Table 2).
In sex-specific analyses (Supplementary Table 4) of COVID-19 
hospitalization, significant interactions by sex were only present 
for CKD (p = 4.20E-02) and asthma (p = 1.10E-02), which were 
both risk factors in women but not in men. For inpatient COVID-
19 positivity and death, a significant interaction by sex was only 
present for CKD (p = 3.80E-02), which was a significant risk factor 
in women only.
Discussion
We aimed to identify risk factors in older UKB participants associ-
ated with hospitalization with COVID-19, alone or with mortality, 
Table 2. Risk of Hospitalized COVID-19 and Mortality by Demographic Variables and Preexisting Diagnoses
COVID-19 Positive Inpatient COVID-19 Positive Inpatient and Dead*
Demographics Full Model Demographics Full Model 
OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Age (years)         
 65–69 1.00  1.00  1.00  1.00  
 70–74 1.17 (0.91–1.52) 2.30E-01 1.12 (0.86–1.45) 4.00E-01 1.24 (0.71–2.18) 4.50E-01 1.15 (0.65–2.02) 6.30E-01
 75–79 1.60 (1.24–2.06) 2.70E-04 1.40 (1.08–1.81) 1.00E-02 2.61 (1.55–4.39) 3.00E-04 2.16 (1.27–3.65) 4.30E-03
 80+ 2.02 (1.41–2.89) 1.40E-04 1.60 (1.11–2.32) 1.20E-02 3.66 (1.87–7.18) 1.50E-04 2.65 (1.33–5.29) 5.60E-03
Sex         
 Female 1.00  1.00  1.00  1.00  
 Male 1.91 (1.59–2.29) 5.10E-12 1.79 (1.48–2.17) 2.50E-09 2.36 (1.65–3.39) 2.90E-06 2.12 (1.45–3.09) 1.00E-04
Ethnicity         
 White 1.00  1.00  1.00  1.00  
 Black 3.17 (1.92–5.25) 7.20E-06 2.85 (1.71–4.74) 5.60E-05 3.32 (1.42–7.77) 5.70E-03 2.60 (1.09–6.19) 3.00E-02
 South Asian 2.01 (1.20–3.36) 8.30E-03 1.69 (1.00–2.85) 5.00E-02 1.63 (0.59–4.51) 3.50E-01 1.20 (0.42–3.36) 7.40E-01
  Other (including  
mixed and Chinese)
2.22 (1.24–3.98) 7.50E-03 2.00 (1.11–3.61) 2.00E-02 No observations  No observations  
Education         
 Degree 1.00  1.00  1.00  1.00  
  Professional  
qualification
1.40 (1.03–1.91) 3.40E-02 1.31 (0.96–1.79) 8.80E-02 1.66 (0.93–2.97) 8.50E-02 1.51 (0.85–2.70) 1.60E-01
 School/College 1.20 (0.92–1.57) 1.90E-01 1.11 (0.85–1.45) 4.50E-01 1.23 (0.73–2.08) 4.30E-01 1.09 (0.64–1.84) 7.60E-01
 None 2.52 (1.96–3.24) 5.80E-13 2.06 (1.60–2.66) 2.70E-08 2.43 (1.49–3.97) 3.80E-04 1.82 (1.10–2.99) 1.90E-02
Prevalent disease†         
 CHD   0.95 (0.74–1.21) 6.60E-01   0.86 (0.55–1.36) 5.30E-01
 Atrial fibrillation   1.64 (1.24–2.17) 5.00E-04   1.63 (0.98–2.71) 5.80E-02
 Stroke   1.16 (0.75–1.81) 5.00E-01   0.93 (0.40–2.17) 8.70E-01
 Hypertension   1.38 (1.13–1.68) 1.70E-03   1.42 (0.96–2.11) 7.90E-02
 Diabetes (type 2)   1.73 (1.36–2.22) 1.20E-05   3.11 (2.06–4.71) 7.60E-08
  Chronic kidney  
disease 
  1.49 (0.96–2.31) 7.30E-02   0.88 (0.35–2.24) 8.00E-01
 Depression   1.79 (1.37–2.33) 1.70E-05   1.78 (1.07–2.96) 2.70E-02
 Dementia   3.50 (1.93–6.34) 3.60E-05   7.30 (3.28–16.21) 1.10E-06
 Asthma   1.12 (0.87–1.44) 3.70E-01   0.59 (0.33–1.04) 6.70E-02
 COPD   1.58 (1.17–2.15) 2.90E-03   1.91 (1.10–3.32) 2.20E-02
 Osteoporosis   1.40 (0.91–2.14) 1.20E-01   1.36 (0.58–3.17) 4.80E-01
 Osteoarthritis   0.98 (0.77–1.26) 8.90E-01   1.08 (0.69–1.70) 7.40E-01
Previous disease/ 
 condition†
        
 Delirium   1.14 (0.45–2.90) 7.80E-01   1.02 (0.23–4.58) 9.70E-01
 Pneumonia   1.96 (1.45–2.64) 1.10E-05   1.88 (1.07–3.30) 2.80E-02
  Falls/Fragility  
fractures
  1.10 (0.89–1.34) 3.80E-01   1.20 (0.82–1.76) 3.40E-01
Notes: CHD = coronary heart disease; CI = confidence interval; COPD = chronic obstructive pulmonary disease; OR = odds ratio. Demographics model (ad-
justed for age group, sex, ethnicity, education, and baseline assessment center). Full model (adjusted for age group, sex, ethnicity, education, baseline assessment 
center, and all the above diseases/conditions).
*Comparison group excluded participants testing positive and surviving.
†Diagnoses from baseline self-report and hospital inpatient admissions.
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during the peak of the initial epidemic in England. Preexisting diag-
noses of dementia, type 2 diabetes, COPD, pneumonia, and de-
pression, as well as atrial fibrillation and hypertension emerged as 
independent risk factors for COVID-19 hospitalization, the first 5 
remaining statistically significant for related mortality. In addition, 
preexisting asthma and CKD emerged as risk factors in women for 
being hospitalized with COVID-19. Interestingly, CHD was common 
in COVID-19 inpatients and associated with COVID-19 in models 
adjusted for demographics only, but this association was no longer 
present after adjustment for comorbidities. In keeping with other 
studies, we also found an increased risk of COVID-19 in males, but 
we have shown that this risk is virtually unchanged after adjusting 
for comorbidities. In addition, we confirmed previous reports that 
people of black ethnicity and those with no educational qualifica-
tions had a higher risk. Overall, these results suggest that there are 
specific risk comorbidities in older groups and that severe COVID-
19 susceptibility is not merely the result of advancing age.
Hypertension is well recognized as the most common chronic 
diagnosis, prevalent in more than 70% of persons at age older than 
80 (15). While highly prevalent in the UKB cohort, we found that it 
was only modestly more common in COVID-19 cases than in other 
UKB participants and not significantly associated with COVID-19 
positivity and death. Interestingly, in females, we found that having a 
diagnosis of CKD (Grade 3–5) was associated with being COVID-19 
positive (alone and with mortality), mirroring previous analyses by 
Masoli et al. (16), who found that CKD grade is more predictive of 
mortality than blood pressure in adults aged older than 70. Chronic 
kidney disease has also been reported to be associated with in-
creased hospitalization with infection, particularly pneumonia, and 
increased 30-day mortality (17,18).
Another novel finding is the association between atrial fibril-
lation and hospitalized COVID-19 positivity in the studied older 
adults and an association with COVID-19 positive and dead in 
men specifically. During atrial fibrillation, the loss of atrioven-
tricular synchrony with decreased diastolic filling time is likely to 
lead to a decrease in cardiac output. Consequently, this low cardiac 
output may aggravate tissue hypoxia in COVID-19 patients. Also, 
agents used in the control of atrial fibrillation, particularly sotalol, 
propafenone, and nonselective β-blockers, may cause broncho-
spasm (19). Pulmonary symptoms in COPD may become worse 
with atrial fibrillation development, due to excessive irregular heart 
rate, as well as the reduced diastolic filling of the ventricles (20). 
These factors may contribute to higher severe COVID-19 risk in 
participants with atrial fibrillation.
To date, there has been limited data on preexisting diagnoses of 
dementia and COVID-19 hospitalization, despite dementia affecting 
more than 50 million people worldwide (21). This may be due to 
the young median ages of many published COVID-19 case series, 
with a limited characterization of older persons. Our analysis con-
firms dementia to be the largest effect risk diagnosis in adults aged 
older than 65 for risk of hospitalized COVID-19 test positivity and 
death, in this cohort of community volunteers. A  recent report of 
observational data from the International Severe Acute Respiratory 
and Emerging Infections Consortium found a high prevalence of 
dementia in older adults admitted to hospital with COVID-19 (3). 
Future work will need to establish whether this a direct effect of de-
mentia pathologies or an indirect effect of high rates of infection in 
nursing homes. Recent studies have reported that the APOE e4 geno-
type (a risk factor for Alzheimer’s disease) predicts severe COVID-19 
(22) and death (23), independent of preexisting dementia, but further 
work is needed to understand the biological mechanisms involved. 
Further work is also needed to establish the extent to which the ob-
served association between depression and COVID-19 hospitaliza-
tion is due to the depression itself or secondary to other diagnosed 
and undiagnosed physical pathologies.
In this analysis, we compared the characteristics of older COVID-
19 inpatients to the rest of the study population, aiming to identify 
predictive factors for a severe infection that might be used to identify 
older people at higher risk in the community. An alternative analysis 
approach could compare COVID-19-positive inpatients (n = 507) to 
inpatients whose COVID-19 tests were negative (n = 596) during the 
study period (Supplementary Table 5). However, it should be noted 
that during the period studied at the epidemic peak, COVID-19 
testing was largely restricted to hospital inpatients with symptoms 
of the infection (14), and the polymerase chain reaction test used 
had a significant false-negative rate of up to 29% on initial testing 
(24). Differences between test positives and negatives may therefore 
reflect other reasons for hospital admission with symptoms resem-
bling COVID-19, plus false negatives. In the test-positive versus test-
negative analysis (Supplementary Table 5), prevalent diabetes was 
associated with an increased risk, and a previous delirium episode 
was associated with a decreased risk of a positive COVID-19 test, 
and dementia and diabetes were associated with an increased risk 
of a positive COVID-19 test and death. As the statistical power to 
detect test-positive versus negative differences is far lower than in 
the comparison with the rest of the UKB sample, caution is needed 
in interpreting nonsignificant associations with the high-risk diseases 
identified in the main analysis.
UK Biobank participants were somewhat healthier than the 
general population (25) at baseline in 2006–2010, but the sample 
nevertheless includes large numbers of socioeconomically less 
privileged participants: for example, 36.1% of cases and 22.3% 
of controls had no educational qualifications (Table  1). Other 
limitations include the lack of details of degrees of clinical severity 
of COVID-19, beyond the ascertained measures of hospitaliza-
tion and mortality. We do not currently have access to measures 
of COVID-19 exposure in the UKB sample or details of COVID-
19 illnesses that did not result in hospital admission. During the 
peak of the epidemic, some patients with, for example, angina 
or even myocardial infarction may have been deterred from 
seeking medical help (26), which may possibly have influenced 
our finding of no association between CHD and COVID-19 hos-
pitalization in fully adjusted models. However, CHD was more 
common in COVID-19 hospitalization on simple adjustment for 
demographics, with this association disappearing only after ad-
justment for other diagnoses. It may therefore be that common re-
lated comorbidities, for example, atrial fibrillation, hypertension, 
and CKD, are actually more predictive of COVID-19 hospitaliza-
tion than preexisting CHD itself in older people. There may have 
been under ascertainment of inpatient COVID-19-related deaths 
in the data available for April 2020 (27), but as the analyses for 
risk of COVID-19 positivity and death excluded participants who 
tested positive and survived, the impact on mortality associations 
is likely to be small. UK Biobank does not have data on care home 
residence, but the sample is relatively young (93.9% <80 years), 
and at the peak of the epidemic hospital admission from care 
homes was restricted (14).
Only a small proportion of the English population had been ex-
posed to the virus during the study period, but the group studied here 
was exposed and developed severe enough COVID-19 to be tested 
during hospitalization, with some of those dying. Our case group 
is therefore relevant for assessing risk factors for severe COVID-19 
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inpatients and death in this older population, but may not apply 
to asymptomatic or milder nonhospitalized cases. Our diagnostic 
data are derived from participant’s baseline interviews plus hos-
pital discharge data until March 2017, so under-ascertainment of 
disease is likely, especially for recently diagnosed conditions, but 
the similarity to previous reports of the common conditions seen in 
COVID-19 patients suggests that our data are valid.
Our results should have implications for preventive interven-
tions, encouraging a more targeted approach prioritizing those 
older adults with specific risk factors, rather than adopting policies 
that use chronological older age as a blanket indicator of risk. Our 
cohort evidence of specific risk factors may also help with avoiding 
potentially “ageist” approaches to setting clinical priorities in 
over-stretched health systems (28). Our findings of risks associated 
with less prominent conditions such as atrial fibrillation and de-
pression, plus asthma and CKD in women only, could help focus 
clinical research. In addition, the prominence of depression as one 
of the major risk factors highlights the role of mental health (29) 
as critical to managing the pandemic, including in older people.
Conclusions
In older adults, several specific preexisting comorbidities are dispro-
portionally common in hospitalized COVID-19 male and female 
patients, alone or with mortality, notably including dementia, de-
pression, atrial fibrillation, and CKD. Clinical and public health re-
search is needed to establish the mechanisms involved and whether 
stratified interventions are needed for older patients with specific 
comorbidities. Our results do not support the simple age targeting of 
interventions to prevent severe COVID-19 infection.
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Supplementary data are available at The Journals of Gerontology, 
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